Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Kanamycin Action Pathway
Homo sapiens
Drug Action Pathway
Created: 2013-08-22
Last Updated: 2019-08-16
Kanamycin is an aminoglycoside antibiotic that can used for inhibiting protein synthesis of bacteria, which can be used for treating bacterial infections and tuberculosis. Kanamycin can bind to bacterial 30S ribosomal subunit protein and four nucleotides of 16S rRNA irreversibly to inhibit the formation of mRNA. Binding of kanamycin can interfere the vicinity of nucleotide 1400 in 16S rRNA that can interact with wobble base of the anticodon of tRNA, which lead to misreading of mRNA and wrong insertion of amino acids. The result is the nonfunctional or toxic peptides that is generated from the ribosome. Aminoglycosides can be used for treating bacterial infections from aerobic, Gram-negative bacteria and also Gram-postive bacteria. However, aminoglycosides may cause more damage to the host than other antibiotics for Gram-positive bacterial infection. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
References
Kanamycin Pathway References
[http://www.drugbank.ca](http://www.drugbank.ca/drugs/DB01172)
Song, K.S. Ribosomal protein synthesis inhibitors. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology. (2004) p. 827-833. Berlin, Germany: Springer.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
No Proteins Present
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
No Proteins Present
Settings